In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Alliqua Biomedical Inc. (NASDAQ:ALQA) reported that Celgene Corp /de/ has picked up 8,025,194 of common stock as of 2017-03-16.
The acquisition brings the aggregate amount owned by Celgene Corp /de/ to a total of 8,025,194 representing a 19.9% stake in the company.
For those not familiar with the company, Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.
A glance at Alliqua Biomedical Inc. (NASDAQ:ALQA)’s key stats reveals a current market capitalization of 17.77 Million based on 35.11 Million shares outstanding and a price at last close of $0.599 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2017-02-27, Celgene picked up 4,000,000 at a purchase price of $0.50. This brings their total holding to 7,046,100 as of the date of the filing.
On the sell side, the most recent transaction saw Kalen unload 24,057,980 shares at a sale price of $0.04. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Alliqua Biomedical Inc. (NASDAQ:ALQA) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
